Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

BACKGROUND: Alemtuzumab is administered as two annual courses for relapsing–remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen. OBJECTIVE: The objective was to evaluate 6-year outcomes in patients who relapsed between alemtuzumab Courses 1 and 2 (early r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mult Scler
Main Authors: Van Wijmeersch, Bart, Singer, Barry A, Boster, Aaron, Broadley, Simon, Fernández, Óscar, Freedman, Mark S, Izquierdo, Guillermo, Lycke, Jan, Pozzilli, Carlo, Sharrack, Basil, Steingo, Brian, Wiendl, Heinz, Wray, Sibyl, Ziemssen, Tjalf, Chung, Luke, Margolin, David H, Thangavelu, Karthinathan, Vermersch, Patrick
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2019
Assuntos:
Original Research Papers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7604550/
https://ncbi.nlm.nih.gov/pubmed/31675266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458519881759
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados